NeuroPace (NASDAQ:NPCE) Now Covered by Analysts at UBS Group

UBS Group started coverage on shares of NeuroPace (NASDAQ:NPCE - Free Report) in a report issued on Tuesday, Marketbeat reports. The firm issued a buy rating and a $17.00 price target on the stock.

Several other analysts have also recently weighed in on the company. Wells Fargo & Company reduced their price target on NeuroPace from $15.00 to $13.00 and set an "overweight" rating on the stock in a report on Wednesday, November 13th. JPMorgan Chase & Co. boosted their price objective on shares of NeuroPace from $9.00 to $14.00 and gave the stock an "overweight" rating in a research note on Tuesday, December 17th. One analyst has rated the stock with a hold rating and six have assigned a buy rating to the company's stock. According to data from MarketBeat, NeuroPace has a consensus rating of "Moderate Buy" and a consensus target price of $15.33.

NeuroPace Price Performance

NASDAQ:NPCE traded up $1.09 on Tuesday, hitting $13.06. The company had a trading volume of 257,173 shares, compared to its average volume of 111,724. NeuroPace has a 52 week low of $5.45 and a 52 week high of $18.15. The company has a current ratio of 5.59, a quick ratio of 4.77 and a debt-to-equity ratio of 6.03. The stock has a market capitalization of $389.84 million, a price-to-earnings ratio of -13.06 and a beta of 2.02. The firm has a 50 day moving average of $10.92 and a two-hundred day moving average of $8.44.

NeuroPace (NASDAQ:NPCE - Get Free Report) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($0.19) EPS for the quarter, beating analysts' consensus estimates of ($0.26) by $0.07. The company had revenue of $21.06 million during the quarter, compared to analysts' expectations of $19.33 million. NeuroPace had a negative return on equity of 205.41% and a negative net margin of 36.74%. During the same period in the prior year, the company earned ($0.28) EPS. On average, research analysts anticipate that NeuroPace will post -1 earnings per share for the current year.

Insider Transactions at NeuroPace

In related news, major shareholder Ltd. Kck sold 223,991 shares of the company's stock in a transaction dated Friday, October 25th. The shares were sold at an average price of $5.45, for a total value of $1,220,750.95. Following the sale, the insider now owns 5,270,845 shares in the company, valued at $28,726,105.25. This represents a 4.08 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Insiders own 22.20% of the company's stock.

Institutional Trading of NeuroPace

Institutional investors and hedge funds have recently modified their holdings of the stock. KCK LTD. purchased a new position in NeuroPace during the fourth quarter worth about $58,981,000. Millennium Management LLC boosted its stake in shares of NeuroPace by 13.3% in the 2nd quarter. Millennium Management LLC now owns 686,037 shares of the company's stock worth $5,186,000 after buying an additional 80,324 shares during the last quarter. Geode Capital Management LLC grew its holdings in shares of NeuroPace by 8.7% in the third quarter. Geode Capital Management LLC now owns 317,192 shares of the company's stock valued at $2,211,000 after acquiring an additional 25,330 shares in the last quarter. State Street Corp increased its position in shares of NeuroPace by 9.1% during the third quarter. State Street Corp now owns 155,490 shares of the company's stock valued at $1,084,000 after acquiring an additional 12,912 shares during the last quarter. Finally, Bank of New York Mellon Corp bought a new stake in NeuroPace during the second quarter worth $257,000. 78.83% of the stock is owned by hedge funds and other institutional investors.

About NeuroPace

NeuroPace, Inc operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely.